Final safety analysis of a trial in 1770 Ugandan children aged 9-23 months: 60% had a non-serious adverse event after yellow fever vaccine; fever was more common with full than one-fifth or one-half doses, and serious events (1.7%) did not differ by arm.
RCTn = 1,770
Lee et al. Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to standard dose in children 9-23 months old in Uganda, 2019-2022 - final report